Top

Supportive Care in Cancer

Published in:

01-09-2011 | Original Article

Characterization of cancer-induced bone pain: an exploratory study

Authors: Barry J. A. Laird, John Walley, Gordon D. Murray, Eleanor Clausen, Lesley A. Colvin, Marie T. Fallon

Published in: Supportive Care in Cancer | Issue 9/2011

Abstract

Purpose

Cancer-induced bone pain (CIBP) is the commonest cause of pain in patients with cancer. Its association with increased morbidity combined with limitations of currently available therapies makes it a clinical challenge. Clinical characterization of this complex pain syndrome is essential in underpinning clinical management and informing future research. The aim of this exploratory study was to characterise CIBP using self-rating scales.

Patients and methods

A cross-sectional survey of patients with CIBP was carried out in a regional oncology centre. Patients described their pain over the preceding 24 h using the McGill Pain Questionnaire, Brief Pain Inventory (BPI), and a breakthrough pain questionnaire. Multiple linear regression analyses were conducted.

Results

Fifty-five patients were recruited. Annoying, gnawing, aching, and nagging were the most commonly used words to describe CIBP. From the BPI, median average pain was 4/10 and worst pain was 7/10 on a 0–10 Numerical Rating Scale. The worst pain score correlated more strongly with BPI interference score (p = 0.001). Forty-one patients had breakthrough pain. Patients with breakthrough pain had higher total BPI interference scores than those with no breakthrough pain; median (IQR); 35.0 (2.5–44.7) vs. 18.5 (5.5–26.7), p < 0.01. Of the patients, 20/41 (48%) had breakthrough pain of rapid onset (less than 5 min) and short duration (less than 15 min).

Conclusion

In CIBP, worst pain most accurately reflects the characteristics of pain flares and functional impairment. Breakthrough pain is often unpredictable, sudden onset and short duration. Further characterization studies of CIBP in the broader cancer population are needed

Available only for authorised users

Banning A, Sjogren P, Henriksen H (1991) Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45(1):45–48PubMedCrossRef

Coleman RE (1997) Skeletal complications of malignancy. Cancer 80(8 Suppl):1588–1594PubMedCrossRef

Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1–2):1–18PubMedCrossRef

Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41(3):273–281PubMedCrossRef

Bruera E et al (1995) A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manag 10(5):348–355CrossRef

Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81(1–2):129–134PubMedCrossRef

Neville-Webbe H, Coleman RE (2003) The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia. Palliat Med 17(6):539–553PubMedCrossRef

McQuay HJ et al (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev (2):p. CD001793

Chow E et al (2007) Meta-analysis of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 19(3 Suppl):S26

10.

McNicol E et al (2004) Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol 22(10):1975–1992PubMedCrossRef

11.

Eisenberg E et al (1994) Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12(12):2756–2765PubMed

12.

Ross JR et al (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327(7413):469PubMedCrossRef

13.

Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24(6):425–432PubMedCrossRef

14.

Luger NM et al (2002) Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 99(3):397–406PubMedCrossRef

15.

Fallon M, Cherny N, Hanks GW et al (2009) Opioid analgesic therapy. In: Hanks GW (ed) In Oxford textbook of palliative medicine. Oxford University Press, Oxford

16.

Portenoy RK et al (2004) Difficult pain problems: an integrated approach. In: Doyle D (ed) In Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 435–438

17.

Farrar JT et al (2000) Defining the clinically important difference in pain outcome measures. Pain 88(3):287–294PubMedCrossRef

18.

Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1(3):277–299PubMedCrossRef

19.

Melzack R, Katz J (2001) The McGill Pain questionnaire: appraisal and current status. In: Turk D, Melzack R (eds) Handbook of pain assessment, 2nd edn. Guilford Press, New York, pp 35–52

20.

Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129–138PubMed

21.

Daut RL, Cleeland CS, Flanery RC (1983) Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases. Pain 17(2):197–210PubMedCrossRef

22.

Portenoy RK et al (1992) Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. Cancer 70(6):1616–1624PubMedCrossRef

23.

Caraceni A et al (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18(3):177–183PubMedCrossRef

24.

Bennett M (2001) The LANSS pain scale: the Leeds assessment of neuropathic symptoms and signs. Pain 92(1–2):147–157PubMedCrossRef

25.

Harris K et al (2007) Worst, average or current pain in the Brief Pain Inventory: which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clin Oncol (R Coll Radiol) 19(7):523–527

26.

Yun YH et al (2004) Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the Brief Pain Inventory. Oncology 66(6):439–444PubMedCrossRef

27.

Mercadante S et al (1992) Predictive factors in advanced cancer pain treated only by analgesics. Pain 50(2):151–155PubMedCrossRef

28.

Mercadante S et al (2002) Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94(3):832–839PubMedCrossRef

29.

Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3(1):38–44PubMedCrossRef

30.

Gomez-Batiste X et al (2002) Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 24(1):45–52PubMedCrossRef

31.

Hwang SS, Chang VT, Kasimis B (2003) Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 101(1–2):55–64PubMedCrossRef

32.

Bailey F, Farley A (2006) Oral opioid drugs. In: Davies A (ed) In cancer-related breakthrough pain. Oxford University Press, Oxford, pp 43–55

33.

Christie JM et al (1998) Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16(10):3238–3245PubMed

34.

Portenoy RK et al (2006) A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 22(9):805–811PubMedCrossRef

35.

Slatkin NE et al (2007) Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 5(7):327–334PubMed

36.

Duncan A (2002) The use of fentanyl and alfentanil sprays for episodic pain. Palliat Med 16(6):550PubMedCrossRef

37.

Fine PG, Busch MA (1998) Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manag 16(3):179–183CrossRef

Title: Characterization of cancer-induced bone pain: an exploratory study
Authors: Barry J. A. Laird
John Walley
Gordon D. Murray
Eleanor Clausen
Lesley A. Colvin
Marie T. Fallon
Publication date: 01-09-2011
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 9/2011
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-010-0961-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2011

Paediatric oncology patient preference for oral nutritional supplements in a clinical setting

Oral rehabilitation with implant-based prostheses of two adult patients treated for childhood rhabdomyosarcoma

Oral symptoms and functional outcome related to oral and oropharyngeal cancer

Insomnia in elderly cancer survivors—a population-based controlled study of associations with lifestyle, morbidity, and psychosocial factors. Results from the Health Survey of North-Trøndelag County (HUNT-2)

Social support and depressive mood 1 year after diagnosis of breast cancer compared with the general female population: a prospective cohort study

Individualized pharmacological treatment of oral mucositis pain in patients with head and neck cancer receiving radiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer